Green Valley

to Develop Drugs that Patients Await

As an innovative-driven biopharmaceutical company and with our firm mission of “to develop drugs that patients await”, Green Valley is striving to develop innovative medicines and create a precise diagnosis and treatment platform for brain diseases with advanced AI techniques based on carbohydrate drugs development and deep insights on pathogenesis of brain diseases plus other complex chronic diseases. The company aims to provide patients all over the world with novel medicines and health programs primarily for brain-related diseases such as Alzheimer's disease, then extending to cardiovascular disease, diabetes, tumors and other complex chronic diseases which remain difficult to treat. Our core competitiveness lies in the ability to explore pathogenesis of diseases. We stick on the way of original innovation with brand new concept to foster advancement of life science and persist in offering beneficial healthcare models for human beings to change their lives.

Founded in 2000, Green Valley is headquartered in Shanghai Zhangjiang Hi-Tech Park with about 1500 employees. The company has also built a GMP-certified manufacturing site in Qingpu, District of Shanghai, and a carbohydrate drug engineering center, an expert academician workstation and a provincial-level carbohydrate drug laboratory in Benxi City, Liaoning Province. Our company has established long-term strategic partnership with Shanghai Institute of Materia Medica of Chinese Academy of Sciences and has extensive cooperation with experts from some top colleges and universities across the world, such as the Peking University, the University of Washington, the Rowan University and the University of Toronto in Canada, to join hands together to develop cutting-edge diagnosis and treatment solutions. Meanwhile, under the leadership of the academicians of Chinese Academy of Engineering, the Green Valley Research Institute, our R&D center owns a dedicated and high-profiled team including "Outstanding Youth" of the "Hundred-Talent Program" and returned Chinese scholars. Our focus is to develop innovative medicines for brain diseases and cancer.

Site search


follow us


Shanghai Institute of Materia Medica, Chinese Academy of Sciences, is one of the most advanced drug R&D institutions in China with international influence. Shanghai Institute of Materia Medica is a long-term strategic partner of Green Valley. The company has set up the "Green Valley Innovation Fund" and has established long-term cooperation with Shanghai Institute of Materia Medica for industrialization of scientific research achievements.

Bracket is an international US-based company specializing in conformity training of scale assessors. Using Bracket’s expertise in scale assessment, Green Valley conducts unified training and assessment of scale assessors participating in clinical studies.

IXICO is a UK-based company specializing in clinical imaging data acquisition, quality control and analysis services. In collaboration with IXICO, Green Valley uniformly calibrates PET in clinical research centers and trains operators to control the quality of acquired data and to analyze imaging data.

Banner Alzheimer's Institute is a globally renowned Alzheimer's disease research institute in the United States. The Institute is committed to developing new standards for caring patients with Alzheimer's disease and their family members and conducting leading and innovative research on detection and treatment of Alzheimer's disease. Green Valley has hired specialists from Banner Alzheimer's Institute to provide academic guidance and support the company in Alzheimer's disease drug development.

Green Valley has established cooperation with experts from the University of Washington, the Rowan University, the University of Toronto in Canada, and top colleges and universities across the world for R&D and application of biomarkers and non-invasive testing.

Quintiles is the largest pharmaceutical and biotechnology service company in the world. It is a long-term strategic partner of Green Valley. The cooperation aims to provide global one-stop clinical research services, and it supports Green Valley’s development of innovative drugs.

Covance is a world-renowned pharmaceutical and biotechnology service company. In its strategic cooperation with Green Valley, Covance provides a full range of services such as GLP testing of biological samples.

Joinn is a well-known pharmaceutical and biotechnology service company in China. Green Valley has established multi-dimensional cooperation with Joinn in drug safety assessment, compound screening and pharmacokinetics study.